Abstracts tagged "Janus kinase (JAK)"

Abstract Number: 2103 • 2018 ACR/ARHP Annual Meeting
Using a Drosophila Model to Unravel the Genetic Complexity of Systemic Lupus Erythematosus
Nathan Mortimer, Mary Fischer, Ashley Waring and Victoria DeMichel, School of Biological Sciences, Illinois State University, Normal, IL
Background/Purpose: The objective of our research is to understand the genetic architecture and molecular mechanisms that contribute to the development and progression of the autoimmune…
Abstract Number: 890 • 2018 ACR/ARHP Annual Meeting
A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib to Placebo and to Adalimumab, in Patients with Active Rheumatoid Arthritis with Inadequate Response to Methotrexate
Roy Fleischmann¹, Aileen L. Pangan², Eduardo Mysler³, Louis Bessette⁴, Charles Peterfy⁵, Patrick Durez⁶, Andrew Ostor⁷, Yihan Li², Yijie Zhou², Ahmed A. Othman², In-Ho Song⁸ and Mark C. Genovese⁹, ¹University of Texas Southwestern Medical Center at Dallas, Metroplex Clinical Research Center, Dallas, TX, ²AbbVie, Inc., North Chicago, IL, ³Organización Medica de Investigación, Buenos Aires, Argentina, ⁴Laval University, Québec, QC, Canada, ⁵Spire Sciences LLC, Boca Raton, FL, ⁶Rheumatology, Rheumatology - Cliniques universitaires Saint-Luc - Université Catholique de Louvain - Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, ⁷Cabrini Medical Center, Malvern, Australia, ⁸AbbVie, Inc., north chicago, IL, ⁹Stanford University Medical Center, Palo Alto, CA
Background/Purpose: To assess efficacy, including inhibition of radiographic progression, and safety with upadacitinib (UPA), a JAK1- selective inhibitor, vs placebo (PBO) and active comparator, originator…
Abstract Number: 2105 • 2018 ACR/ARHP Annual Meeting
Genetic Analysis of a Drosophila Systemic Lupus Erythematosus Model Reveals Lupus Susceptibility Genes
Pooja KR, Brooklynne Thielen, Xavier Hernandez and Nathan Mortimer, School of Biological Sciences, Illinois State University, Normal, IL
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disorder with various immunological abnormalities and a diverse range of clinical symptoms. In contrast to the…
Abstract Number: 891 • 2018 ACR/ARHP Annual Meeting
A Phase 3, Randomized, Controlled Trial Comparing Upadacitinib Monotherapy to MTX Monotherapy in MTX-Naïve Patients with Active Rheumatoid Arthritis
Ronald van Vollenhoven¹, Tsutomu Takeuchi², Aileen L. Pangan³, Alan Friedman³, Mohamed-Eslam Mohamed⁴, Su Chen⁴, Maureen Rischmueller⁵, Ricardo Blanco⁶, Ricardo M. Xavier⁷ and Vibeke Strand⁸, ¹Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, Netherlands, ²Keio University School of Medicine, Tokyo, Japan, ³AbbVie, Inc., North Chicago, IL, ⁴AbbVie, Inc., North chicago, IL, ⁵The Queen Elizabeth Hospital and University of Adelaide, Adelaide, Australia, ⁶Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁷Universidade Federal do Rio Grande do Sul Porto Alegre, Rio Grande do Sul, Brazil, ⁸Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA
Background/Purpose: To compare the clinical efficacy, including inhibition of structural damage, and safety of upadacitinib (UPA), a JAK1-selective inhibitor, as monotherapy, vs methotrexate (MTX) monotherapy,…
Abstract Number: 2486 • 2018 ACR/ARHP Annual Meeting
Real-World Outcomes Associated with Triple Therapy Vs. TNFi Combo Therapy: Results from the Corrona Registry
Jeffrey R. Curtis¹, J. Lynn Palmer², George W. Reed³, Jeffrey Greenberg⁴, Dimitrios A. Pappas⁵, Leslie R Harrold⁶ and Joel Kremer⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²Corrona Research Foundation, Albany, NY, ³UMass Medical School, Worcester, MA, ⁴Corrona LLC, Waltham, MA, ⁵Columbia University, New York, NY, ⁶University of Massachusetts Medical School, Worcester, MA
Background/Purpose: Despite several randomized controlled trials showing comparable clinical outcomes with triple therapy (Triple; MTX, SSZ, HCQ) versus combination therapy with MTX+TNFi (TNFi Combo), the…
Abstract Number: 962 • 2018 ACR/ARHP Annual Meeting
Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 6 Years: An Updated Integrated Safety Analysis
Mark C. Genovese¹, Josef S. Smolen², Tsutomu Takeuchi³, Terence P. Rooney⁴, Christina L. Dickson⁴, Xiao-Yan Yang⁴, Chadi Saifan⁴, Anabela Cardoso⁴, Maher Issa⁴, Taeko Ishii⁵ and Kevin Winthrop⁶, ¹Stanford University Medical Center, Palo Alto, CA, ²Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, ³Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵Eli Lilly and Company, Kobe, Japan, ⁶Oregon Health and Science University, Portland, OR
Background/Purpose: Baricitinib (bari), an oral, selective inhibitor of Janus kinase (JAK) 1 and JAK 2, is approved for the treatment of moderately to severely active…
Abstract Number: 2517 • 2018 ACR/ARHP Annual Meeting
The JAK1-Selective Inhibitor Filgotinib Reverses the Disease-Associated Transcriptional Profile Found in the Blood of Patients with Active Rheumatoid Arthritis
Peter C. Taylor¹, Bryan Downie², Luting Zhuo², Yevgeniy Gindin², Jacqueline Tarrant³, Jinfeng Liu², René Galien⁴ and Amer M Mirza⁵, ¹University of Oxford Botnar Research Centre, Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom, ²Bioinformatics, Gilead Sciences Inc., Foster City, CA, ³Gilead Sciences Inc., Foster City, CA, ⁴Galapagos SASU, Romainville, France, ⁵Biomarker Sciences, Gilead Sciences Inc., Foster City, CA
Background/Purpose: Filgotinib (FIL), an oral JAK1- selective inhibitor, has shown good safety and efficacy in active rheumatoid arthritis (RA) patients with inadequate response to MTX…
Abstract Number: 997 • 2018 ACR/ARHP Annual Meeting
The Effects of the Jak-Stat Signal Pathway Inhibition on Collagen Biosynthesis in Fibroblast Cell Culture
Mehtap ŞAHİN¹, Hüseyin AYDIN¹, Ahmet ALTUN², Mehmet Emin DERİN³ and Ali Şahin⁴, ¹Biochemistry, Cumhuriyet University Medical Faculty, sivas, Turkey, ²Pharmacology, Cumhuriyet University Medical Faculty, sivas, Turkey, ³Rheumatology-internal medicine, Cumhuriyet University Medical Faculty, sivas, Turkey, ⁴Department of Rheumatology, Cumhuriyet University Faculty of Medicine, Sivas, Turkey
Background/Purpose: Uncontrolled collagen synthesis and deposition occur in various diseases such as hepatic fibrosis, scleroderma.Tofacitinib is a selective JAK-kinase (1/3)inhibitor.Currently it is used in the…
Abstract Number: 2518 • 2018 ACR/ARHP Annual Meeting
GS-9876, a Novel, Highly Selective, SYK Inhibitor in Patients with Active Rheumatoid Arthritis: Safety, Tolerability and Efficacy Results of a Phase 2 Study
Alan J. Kivitz¹, Daksha P Mehta², Franziska Matzkies³, Afsaneh Mozaffarian³, Rebecca Kunder³, Julie Di Paolo⁴, Neelufar Mozaffarian³, Sean Hsueh³, JiYun Kim⁵, Wendy Jiang³, Lin Liu³, John S. Sundy⁶ and Mark C. Genovese⁷, ¹Altoona Center for Clinical Research, Duncansville, PA, ²Center for Arthritis and Osteoporosis, Elizabethtown, KY, ³Gilead Sciences, Inc., Foster City, CA, ⁴Immunology and Inflammation Biology, Gilead Sciences, Inc., Foster City, CA, ⁵Biomarkers, Gilead Sciences, Inc., Foster City, CA, ⁶Clinical Research, Inflammation and Respiratory, Gilead Sciences, Inc., Foster City, CA, ⁷Stanford University Medical Center, Palo Alto, CA
Background/Purpose: Spleen tyrosine kinase (SYK) mediates immunoreceptor signaling and is essential in activation of cells including B lymphocytes, monocytes, macrophages, dendritic cells, and osteoclasts. SYK…
Abstract Number: 1401 • 2018 ACR/ARHP Annual Meeting
Is There a Specific Effect of Jak-Inhibitors on Pain and Fatigue in Rheumatoid Arthritis?
Itsaso Odriozola¹, Claire-Sophie Coste¹, Thomas Barnetche^2,3, Christophe Richez^4,5, Bernard Bannwarth¹ and Thierry Schaeverbeke⁶, ¹Rheumatology, CHU de Bordeaux, Bordeaux, France, ²FHU ACRONIM, Pellegrin Hospital, Bordeaux University, Bordeaux, France, ³Rheumatology, Centre hospitalier universitaire de Bordeaux - Service de Rhumatologie, Bordeaux, France, ⁴UMR CNRS 5164 - Immunoconcept, Bordeaux, France, ⁵Department of Rheumatology, Bordeaux University Hospital, Bordeaux, France, ⁶Department of Rheumatology, Bordeaux University Hospital, BORDEAUX, France
Background/Purpose: Pain and fatigue are common symptoms for patients with rheumatoid arthritis (RA).JAK inhibitors (JAKi) already proved similar efficacy on disease activity as bDMARD (anti-TNF,…
Abstract Number: 2546 • 2018 ACR/ARHP Annual Meeting
The Association between Patient Reported Outcomes and Clinical Measures Among Rheumatoid Arthritis Patients: Analyses Using Phase 3 Clinical Trials of Upadacitinib
Vibeke Strand¹, Nemanja Damjanov², Craig Scoville³, Namita Tundia⁴, Heidi S. Camp⁴, Kun Chen⁴, Jessica Suboticki⁴ and Ronald van Vollenhoven⁵, ¹Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ²Institute of Rheumatology, Belgrade University School of Medicine, Belgrade, Serbia, ³Idaho Falls Arthritis Clinic, Idaho Falls, ID, ⁴AbbVie Inc., North Chicago, IL, ⁵Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, Netherlands
Background/Purpose: Patient-reported outcomes (PROs) in RA are important to evaluate total disease impact, although treatment decisions may often be guided by traditional physician-derived measures of…
Abstract Number: 1518 • 2018 ACR/ARHP Annual Meeting
Baricitinib and Tofacitinib in Real Life – Does Obesity Impact Response to Janus Kinase Inhibitor Therapy in Rheumatoid Arthritis?
Yvette Meißner¹, Lisa Baganz¹, Matthias Schneider², Ilka Schwarze³, Martin Feuchtenberger⁴, Angela Zink⁵ and Anja Strangfeld⁶, ¹Programme Area Epidemiology, German Rheumatism Research Center, Berlin, Germany, ²Policlinic for Rheumatology & Hiller Research Centre for Rheumatology, Department of Rheumatology & Hiller Research Unit, Medical Faculty, University Hospital, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, ³Praxis internistische Rheumatologie, Leipzig, Germany, ⁴Rheumatologie/Klinische Immunologie, Kreiskliniken Altötting-Burghausen, Burghausen, Germany, ⁵Epidemiology Unit / Rheumatology and Clinical Immunology, German Rheumatism Research Centre (DRFZ) / Charité University Hospital, Berlin, Germany, ⁶Epidemiology, German Rheumatism Research Center, Berlin, Germany
Background/Purpose: The influence of obesity on treatment response of tumor necrosis factor inhibitors in patients with rheumatoid arthritis (RA) is described in literature, but data…
Abstract Number: 2547 • 2018 ACR/ARHP Annual Meeting
Upadacitinib Monotherapy Improves Patient-Reported Outcomes in Patients with Rheumatoid Arthritis and Inadequate Response to Methotrexate
Vibeke Strand¹, Maya Buch², Namita Tundia³, Heidi S. Camp³, Jessica Suboticki³, Debbie Goldschmidt⁴ and Alvin F. Wells⁵, ¹Stanford University, Palo Alto, CA, ²NIHR Leeds Musculoskeletal Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ³AbbVie Inc., North Chicago, IL, ⁴Analysis Group Inc., New York, NY, ⁵Rheumatology and Immunotherapy Center, Franklin, WI
Background/Purpose: Upadacitinib (UPA) is a selective JAK-1 inhibitor with demonstrated patient-reported benefits in the treatment of active rheumatoid arthritis (RA).1,2 The objective of this analysis…
Abstract Number: 1524 • 2018 ACR/ARHP Annual Meeting
Malignancies and Serious Infections in Randomized Controlled Trials of Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Maria A. Lopez-Olivo¹, Jean Tayar², Natalia Zamora³, Gregory Pratt⁴ and Maria Suarez-Almazor⁵, ¹Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, ²Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA, Houston, TX, ³Reumatologia, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, Buenos Aires, Argentina, ⁴Research Medical Library, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, ⁵Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA, Houston, TX
Background/Purpose: Two JAK inhibitors are currently approved by different agencies worldwide for their use in patients with rheumatoid arthritis. The safety profile of these agents…
Abstract Number: 2551 • 2018 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Treatment with Filgotinib: Week 132 Safety Data from a Phase 2b Open-Label Extension Study
Arthur Kavanaugh¹, Mark C. Genovese², Kevin Winthrop³, Maria Greenwald⁴, Lucia Ponce⁵, Favio Enriquez Sosa⁶, Mykola Stanislavchuk⁷, Minodora Mazur⁸, Alberto Spindler⁹, Regina Cseuz¹⁰, Natalya Nikulenkova¹¹, Maria Glowacka-Kulesz¹², Istvan Szombati¹³, Anna Dudek¹⁴, Neelufar Mozaffarian¹⁵, Joy Greer¹⁶, Rebecca Kunder¹⁵, Di An¹⁷, Luc Meuleners¹⁸, Robin Besuyen¹⁸, Rieke Alten¹⁹ and René Westhovens²⁰, ¹University of California, San Diego, School of Medicine, La Jolla, CA, ²Stanford University Medical Center, Palo Alto, CA, ³Oregon Health and Science University, Portland, OR, ⁴Desert Medical Advances, Palm Desert, CA, ⁵Cons. Priv. Temuco, Temuco, Chile, ⁶Clinstile SA de CV, Col., Mexico City, Mexico, ⁷Rheumatology, Vinnytsia Regional Clinical Hospital, Vinnytsia, Ukraine, ⁸IMSP Inst. de Cardiologie, Chisinau, Moldova, The Republic of, ⁹Centro Médico Privado de Reumatología, Centro Médico Privado de Reumatología, Argentina, ¹⁰Revita Reumatologiai Kft, Budapest, Hungary, ¹¹Vladimir Reg Clin Hosp, Vladimir, Russian Federation, ¹²Silesiana Centrum Medyczne, Wroclawska, Poland, ¹³Qualiclinic Kft., Budapest, Hungary, ¹⁴AMED Medical Center, Warsaw, Poland, ¹⁵Gilead Sciences, Inc., Foster City, CA, ¹⁶Gilead Sciences, Inc, Foster City, CA, ¹⁷Gilead Science, Inc., Foster City, CA, ¹⁸Galapagos NV, Mechelen, Belgium, Mechelen, Belgium, ¹⁹Schlosspark-Klinik University Medicine, Berlin, Germany, ²⁰Rheumatology, University Hospital KU Leuven, Leuven, Belgium
Background/Purpose: The orally administered, selective inhibitor of Janus Kinase 1 (JAK1), filgotinib (FIL), is currently being investigated for the treatment of rheumatoid arthritis (RA) in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].